Phaseline

Companies › Changchun BCHT Biotechnology

Changchun BCHT Biotechnology: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 2; Other, Infectious disease; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DTacP
Cell-free diphtheria and tetanus toxoid (three-component) combined vaccine
–Phase 3Prevent Whooping CoughJun 2032
Adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccine
Combination vaccine containing diphtheria toxoid, tetanus toxoid, and two-component acellu
–Phase 2Pertussis (Whooping Cough)Aug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07894055Adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccinePhase 2Pertussis (Whooping Cough)Infectious diseaseAug 2027
NCT07112144DTacPPhase 3Prevent Whooping CoughOtherJun 2032

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Bavarian Nordic Sinovac Life Sciences Bharat Biotech International Beijing Zhifei Lvzhu Biopharmaceutical Castle Creek Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.